type of report	Current report
number	66/2012
company	PHARMENA

## Summary of subscription of series C shares

The Management Board of PHARMENA S.A. informs that on 11<sup>th</sup> October 2012, it adopted a resolution on allocation of series C shares with pre-emptive rights.

1) Date of starting and finishing of subscription: date of starting of subscription: 10<sup>th</sup> September 2012, date of finishing of subscription: 26<sup>th</sup> September 2012,

2) Date of allocation of shares: 11<sup>th</sup> October 2012

3) Number of shares covered by the subscription: up to 781,782 series C shares

4) Reduction rate within the additional subscriptions: 65.2297%

5) Number of shares allocated under the carried out subscription: 781.782 series C shares

6) Issue price for which the shares were subscribed: 6.5 PLN per 1 share

7) Number of investors who subscribed for shares covered by the subscription in individual tranches:

- 49 investors within basic subscriptions

- 13 investors within additional subscriptions

8) Number of investors who were allocated the shares within the carried out subscription in individual tranches:

- 49 investors within basic subscriptions

- 13 investors within additional subscriptions

9) Names (business names) of underwriters who took up shares in the performance of underwriting agreements: no underwriters took part in subscription of series C shares

10) Total costs of the issue of series C shares is 175,950.98 PLN net, including:

- costs of preparing and carrying out the offering: 113,020.98 PLN net,

- remuneration for underwriters: 0 PLN net,

- costs of preparing the issue prospectus, including the costs of counselling services: 42,500.00 PLN net,

- costs of promoting of the offering: 20,430.00 PLN net.

Pursuant to Art. 36 (2b) of accounting act, the costs of issue of shares incurred during the increase of share capital reduce the supplementary capital up to the amount of surplus value of issue over the nominal value of share ("agio"), whereas, the remaining part is calculated as financial costs.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 4 (1).

## Representatives of the company:

- Konrad Palka President of the Board
- Marzena Wieczorkowska Vice President of the Board